This article provides an analytical overview of 10 new cardiology solutions advancing heart care. These companies offer solutions like stroke prediction AI, early coronary artery disease detection, and cardio-immunology. Other key areas include targeted stem cell-based myocardial repair and cardiovascular and cardiopulmonary gene therapies. Their contributions span predictive analytics, early detection, immunological approaches, regenerative therapies, and genetic interventions. This article delves into their innovations, showcasing the diverse and expanding impact of these new cardiology solutions.
Continue reading to gain up-to-date and data-driven insights on:
Click to download
Key Takeaways
Drawing insights from the Big Data & AI-powered StartUs Insights Discovery Platform that provides data on over 4.7+ million emerging companies globally, we explore the evolving landscape of the cardiology industry. This sector is marked by key trends and a substantial workforce, shaping its future. We updated this report 5 days ago. Missing information? Contact us to add your insights. Here are some key insights at a glance:
- Current Cardiology Trends: Some of the major trends impacting the cardiology industry are RNA-based therapies, lipidology advances, cardiac regeneration, telemedicine integration, and cardiovascular pharmacology innovations.
- Cardiology Industry Statistics: The sector comprises 32K+ organizations worldwide. Out of these, 3K+ new cardiology companies were founded in the last five years, with 2020 as the average founding year. On average, each of these companies employs about 29 people. Moreover, the average funding received by these new cardiology companies per round in the same span is USD 8.6 million.
- 10 New Cardiology Solutions to Watch:
- Medniscient AI – AI-powered Stroke Prediction
- AccuLine – Early Coronary Artery Disease Detection
- RNatives – MicroRNA-based Cardiac Treatments
- POLYGON Therapeutics – Cardio-immunology
- Cordys Analytics – AI-driven Heart Diagnostics
- Target Cells – Targeted Stem Cell-based Myocardial Repair
- AaviGen – Cardiovascular & Cardiopulmonary Gene Therapies
- Kardi Ai – AI-powered ECG Recording Device
- lubdub.ai – Advanced Heart Health Data Analysis
- BEATLAB – Early Cardiovascular Disease Detection
Discover 10 out of 3K+ Emerging Cardiology Solutions
In this section, we spotlight 10 new cardiology companies offering solutions such as stroke prediction AI, early coronary artery disease detection, and ECG AI diagnostics. Some of these entities integrate targeted stem cell-based myocardial repair and cardiovascular and cardiopulmonary gene therapies. They also leverage advanced algorithms, diagnostic technologies, and regenerative techniques to enhance early detection, precision treatment, and overall cardiac care. Read on to explore many more innovative solutions that these companies offer!
Note on Signal Strength
One of the unique metrics we feature for each company is Signal Strength, a proprietary data point generated by our Discovery Platform. It gauges the extent to which a company’s influence has permeated the global ecosystem of startups, scaleups, and emerging companies. This proprietary metric serves as a valuable guidepost for understanding a company’s standing in the broader market landscape.
1. Medniscient AI
- Founding Year: 2020
- Employee Range: 2-10
- Location: USA
- Signal Strength: Strong
- What they do: Medniscient AI enhances interventional and surgical treatments in cardiology with its AI digital healthcare platform. It uses cardiovascular computed tomography angiography to identify prognostic patterns which enables personalized treatment plans for patients needing interventions. The AI TAVR system predicts surgical complications, such as stroke, by analyzing CT scans with deep learning and computer vision. Stroke risk prediction, essential for transcatheter aortic valve replacement procedures, benefits from this technology. AI TAVR operates independently of electronic medical records by integrating into picture archiving and communication systems (PACS) or computed tomography (CT) processing software.
2. AccuLine
- Founding Year: 2022
- Employee Range: 2-10
- Location: Israel
- Signal Strength: Very Strong
- What they do: AccuLine develops cardiology solutions for early detection of coronary artery disease (CAD). Its product, CORA, assesses CAD risk using a brief four-minute evaluation of three vital signs: electrical heart activity, oxygen saturation, and respiratory phase. It integrates two novel bio-signals: voltage spread, which measures inter-cycle voltage variability, and VCG, which provides a 3D image of the heart’s electrical activity. The technology utilizes deep learning and proprietary augmented waveform display for precise analysis. This non-invasive, cost-effective solution eliminates the need for consumables and radiation exposure. CORA’s AI-powered signal processing and novel filtering algorithm enhance diagnostic accuracy. It reduces time and labor by offering a practical alternative to traditional stress tests.
3. RNatives
- Founding Year: 2020
- Employee Range: 2-10
- Location: Finland
- Signal Strength: Very Strong
- What they do: RNatives utilizes nuclear microRNAs to modulate gene expression for cardiology-related treatments. Its platform upregulates the endogenous VEGFA gene to treat diseases like myocardial ischemia and peripheral artery disease. This involves small RNAs that promote neovascularization in affected tissues, leading to recovery. The technology is based on proprietary research and targets the VEGFA gene with promoter-targeted small RNAs for efficient in vivo application. The company offers an accurate, non-invasive alternative to traditional gene therapy. Its RNA activation technology benefits patients by providing a natural biological response and reducing immunogenic risks. The approach ensures long-lasting gene upregulation through epigenetic modifications.
4. POLYGON Therapeutics
- Founding Year: 2021
- Employee Range: 2-10
- Location: France
- Signal Strength: Very Strong
- What they do: POLYGON Therapeutics leverages immunotherapy to create treatments for cardiovascular diseases. It evolves cardio-immunology by exploring the interplay between the immune system and cardiovascular health. Its EMOTION program modulates CD8+ T cells in myocardial infarction. POLYGON Therapeutics develops PLG-101, the human anti-CD8 monoclonal antibody. This targets CD8+ T cells, which play a pathogenic role in acute myocardial infarction. The CARDINAL platform advances drug development and biomarker programs for cardio-immunology. This platform enhances the understanding and treatment of cardiovascular conditions by integrating bio-imaging and advanced biomarkers. Patients with cardiovascular diseases benefit from these treatments which address unmet medical needs.
5. Cordys Analytics
- Founding Year: 2023
- Employee Range: 2-10
- Location: Netherlands
- Signal Strength: Very Strong
- What they do: Cordys Analytics utilizes AI-powered diagnostics for heart disease to provide advanced analysis for electrocardiograms (ECGs). Its diagnostic software platform employs deep learning techniques to identify subtle ECG patterns and abnormalities for early detection. The platform supports healthcare professionals by offering real-time data analysis and remote accessibility through its cloud-based architecture. This vendor-agnostic software integrates with various ECG devices offering usage in diverse clinical settings. It reduces hospitalizations and complications by enabling timely diagnosis, thus lowering overall healthcare costs. The software aids in informed decision-making by offering clinicians precise insights.
6. Target Cells
- Founding Year: 2023
- Employee Range: 2-10
- Location: Poland
- Signal Strength: Medium
- What they do: Target Cells develops stem cell technologies for cardiac regeneration. It creates a research-grade stem cell binding assay to evaluate targeted stem cell delivery for myocardial repair. This assay mimics targeted delivery to human tissues under in vitro conditions thus enhancing regenerative medicine applications. The assay reduces the cost, time, and animal use in preclinical testing. Its solutions serve scientific institutions, commercial entities, and medical centers in regenerative medicine. Target Cells’ technology promotes efficient myocardial repair, benefiting researchers and clinicians. The plate-based assay improves evaluation accuracy by assessing human stem cells’ ability to bind cardiac tissue.
7. AaviGen
- Founding Year: 2019
- Employee Range: 2-10
- Location: Germany
- Signal Strength: Very Strong
- What they do: AaviGen develops gene therapy technologies for heart failure, employing adeno-associated viral (AAV) vectors with precise cardiac tropism. Its cardiac AAV platform, next-CAP, integrates experimental and bioinformatic technologies to engineer diverse AAV libraries. The platform uses a systemic selection process to identify organ-specific AAV capsids to ensure optimal bio-distribution and transgene expression. These vectors are customized to meet specific therapeutic targets for enhanced safety, efficacy, and manufacturability. Researchers and clinicians benefit from AaviGen’s advanced gene therapy solutions by improving treatment for both acquired and genetic cardiac diseases. The next-CAP platform ensures high-quality vector selection and performance.
8. Kardi Ai
- Founding Year: 2022
- Employee Range: 11-50
- Location: Czech Republic
- Signal Strength: Very Strong
- What they do: Kardi Ai offers cardiac rhythm monitoring and analysis using AI-powered solutions. Its MyKARDI platform utilizes the Polar H10 ECG recorder for continuous and real-time heart rhythm monitoring. This technology provides unlimited and comfortable ECG measurements for improving arrhythmia detection. The AI-driven system enhances early diagnosis by identifying subtle cardiac abnormalities that might be missed in traditional methods. The platform’s cloud-based architecture offers remote accessibility for healthcare providers. Kardi Ai aids with effective treatment adjustments by providing the evaluation of antiarrhythmic pharmacotherapy. It also improves patient care and reduces recurrence by enhancing post-catheter ablation monitoring.
9. lubdub.ai
- Founding Year: 2023
- Employee Range: 2-10
- Location: Australia
- Signal Strength: Medium
- What they do: lubdub.ai’s platform employs data analytics to acquire and index heart health information instantly. This benefits specialists by enabling comprehensive screening and diagnosis from any location with remote result reviews. The firm combines engineering, manufacturing, clinical practice, and corporate governance to ensure the rapid development and commercialization of advanced medical devices. Patients benefit from immediate and detailed heart health assessments directly in their hands with user-friendly diagnostic tools.
10. BEATLAB
- Founding Year: 2020
- Employee Range: 2-10
- Location: Sweden
- Signal Strength: Very Strong
- What they do: BEATLAB offers early detection of cardiovascular disease (CVD) using a combination of standard sensors, AI, and digital twin modeling. This technology offers non-invasive, cost-effective, and precise methods for identifying early signs of CVD. BEATLAB enhances the accuracy of cardiovascular diagnostics making it readily accessible by integrating advanced AI models. The company utilizes digital twin modeling to simulate and analyze heart functions in real-time. The technology’s non-invasive nature ensures patient comfort while providing detailed cardiovascular insights.
Quick Tip to Find New Cardiology Solutions
Utilizing a SaaS platform like the Discovery Platform for identifying new cardiology companies provides significant benefits compared to traditional scouting methods:
- Streamlined Efficiency: The Discovery Platform offers advanced tools that streamline the scouting process. It replaces hours of your conventional desk research, saving time and resources in identifying cardiology innovations.
- Access to Real-time Insights: Gain a competitive edge with up-to-date information on the latest trends in the cardiology industry. The platform keeps you informed with near real-time updates on emerging cardiology solutions and news, enabling you to make swift and informed decisions.
- Tailored Exploration: Customize your search to focus on specific niches within the cardiology sector, such as CVD signs early detection, analytics and medical insights wearable, or cardio-immunology. The platform’s diverse filtering options allow you to target your scouting efforts precisely, ensuring that you find the most relevant and groundbreaking companies in the field.
Ready to Explore All New Cardiology Solutions?
We’ve explored the dynamic landscape of the cardiology industry, examining the latest trends and spotlighting exceptional companies driving innovation. To dive deeper, download our free Healthcare Report or schedule a demo of the Discovery Platform for a customized exploration of these groundbreaking developments. Interested in contributing your expertise on startups and tech? We’d love to hear from you.
